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Abstract
Functional constitutive nitric oxide synthase (NOS) is required for full expression of reflex cutaneous vasodilation 
that is attenuated in aged skin. Both the essential cofactor tetrahydrobiopterin (BH4) and adequate substrate 
concentrations are necessary for the functional synthesis of nitric oxide (NO) through NOS, both of which are 
reduced in aged vasculature through increased oxidant stress and upregulated arginase, respectively. We 
hypothesized that acute local BH4 administration or arginase inhibition would similarly augment reflex 
vasodilation in aged skin during passive whole body heat stress. Four intradermal microdialysis fibers were placed 
in the forearm skin of 11 young (22 ± 1 yr) and 11 older (73 ± 2 yr) men and women for local infusion of 1) 
lactated Ringer, 2) 10 mM BH4, 3) 5 mM (S)-(2-boronoethyl)-l-cysteine + 5 mM Nω-hydroxy-nor-l-arginine to 
inhibit arginase, and 4) 20 mM NG-nitro-l-arginine methyl ester (l-NAME) to inhibit NOS. Red cell flux was 
measured at each site by laser-Doppler flowmetry (LDF) as reflex vasodilation was induced. After a 1.0°C rise in 
oral temperature (Tor), mean body temperature was clamped and 20 mM l-NAME was perfused at each site. 
Cutaneous vascular conductance was calculated (CVC = LDF/mean arterial pressure) and expressed as a 
percentage of maximum (%CVCmax; 28 mM sodium nitroprusside and local heat, 43°C). Vasodilation was 
attenuated at the control site of the older subjects compared with young beginning at a 0.3°C rise in Tor. BH4 and 
arginase inhibition both increased vasodilation in older (BH4: 55 ± 5%; arginase-inhibited: 47 ± 5% vs. control: 
37 ± 3%, both P < 0.01) but not young subjects compared with control (BH4: 51 ± 4%CVCmax; arginase-
inhibited: 55 ± 4%CVCmax vs. control: 56 ± 6%CVCmax, both P > 0.05) at a 1°C rise in Tor. With a 1°C rise in 
Tor, local BH4 increased NO-dependent vasodilation in the older (BH4: 31.8 ± 2.4%CVCmax vs. control: 11.7 ± 
2.0%CVCmax, P < 0.001) but not the young (BH4: 23 ± 4%CVCmax vs. control: 21 ± 4%CVCmax, P = 0.718) 
subject group. Together these data suggest that reduced BH4 contributes to attenuated vasodilation in aged 
human skin and that BH4 NOS coupling mechanisms may be a potential therapeutic target for increasing skin 
blood flow during hyperthermia in older humans.
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tional constitutive nitric oxide synthase (NOS) is required for full
expression of reflex cutaneous vasodilation that is attenuated in aged
skin. Both the essential cofactor tetrahydrobiopterin (BH4) and ade-
quate substrate concentrations are necessary for the functional syn-
thesis of nitric oxide (NO) through NOS, both of which are reduced
in aged vasculature through increased oxidant stress and upregulated
arginase, respectively. We hypothesized that acute local BH4 admin-
istration or arginase inhibition would similarly augment reflex vaso-
dilation in aged skin during passive whole body heat stress. Four
intradermal microdialysis fibers were placed in the forearm skin of 11
young (22  1 yr) and 11 older (73  2 yr) men and women for local
infusion of 1) lactated Ringer, 2) 10 mM BH4, 3) 5 mM (S)-(2-
boronoethyl)-L-cysteine  5 mM N-hydroxy-nor-L-arginine to in-
hibit arginase, and 4) 20 mM NG-nitro-L-arginine methyl ester (L-
NAME) to inhibit NOS. Red cell flux was measured at each site by
laser-Doppler flowmetry (LDF) as reflex vasodilation was induced.
After a 1.0°C rise in oral temperature (Tor), mean body temperature
was clamped and 20 mM L-NAME was perfused at each site. Cuta-
neous vascular conductance was calculated (CVC  LDF/mean
arterial pressure) and expressed as a percentage of maximum (%CVC-
max; 28 mM sodium nitroprusside and local heat, 43°C). Vasodilation
was attenuated at the control site of the older subjects compared with
young beginning at a 0.3°C rise in Tor. BH4 and arginase inhibition
both increased vasodilation in older (BH4: 55  5%; arginase-
inhibited: 47  5% vs. control: 37  3%, both P  0.01) but not
young subjects compared with control (BH4: 51  4%CVCmax;
arginase-inhibited: 55  4%CVCmax vs. control: 56  6%CVCmax,
both P  0.05) at a 1°C rise in Tor. With a 1°C rise in Tor, local BH4
increased NO-dependent vasodilation in the older (BH4: 31.8 
2.4%CVCmax vs. control: 11.7  2.0%CVCmax, P  0.001) but not
the young (BH4: 23  4%CVCmax vs. control: 21  4%CVCmax,
P  0.718) subject group. Together these data suggest that reduced
BH4 contributes to attenuated vasodilation in aged human skin and
that BH4 NOS coupling mechanisms may be a potential therapeutic
target for increasing skin blood flow during hyperthermia in older
humans.
skin blood flow; aging; temperature regulation; tetrahydrobiopterin;
nitric oxide synthase
SKIN BLOOD FLOW (SkBF) is controlled by dual sympathetic
innervation consisting of an adrenergic vasoconstrictor system
and a cholinergic active vasodilator system (7). With increas-
ing body temperature, SkBF first increases through passive
withdrawal of tonic adrenergic vasoconstrictor tone and then
increases further through the active vasodilator system (35).
Active vasodilation is mediated by the release of acetylcholine
and unknown cotransmitter(s) (21), which mediate cutaneous
vasodilation in part through nitric oxide (NO)-dependent
mechanisms. NO is required for full expression of reflex
vasodilation and directly contributes 30–40% to the total
vasodilatory response (20, 37) in young healthy humans.
Primary human aging is associated with an attenuated reflex
cutaneous vasodilation response (24) due to a decreased
cotransmitter and attenuated NO-dependent contributions (11).
The decrease in NO bioavailability in aged human skin results
from both a decrease in NO production through mechanisms
including upregulated arginase and increased NO degradation
through increased oxidant stress (16, 18). These mechanisms
may be linked through the uncoupling of nitric oxide synthase
(NOS). NOS is a dimeric enzyme, requiring coupling of the
oxygenase and reductase domains for NO production (1, 34).
In conditions where substrate (L-arginine) is limited by in-
creased arginase activity or oxidant stress, the NOS dimer is
destabilized and produces superoxide rather than functional
NO (31, 38).
In addition to upregulated arginase activity and increased
oxidative stress, there are other potential mechanisms that may
contribute to NOS uncoupling and attenuated reflex cutaneous
vasodilation in aged skin. In addition to adequate L-arginine
concentrations, tetrahydrobiopterin (BH4) is also required as a
cofactor for optimal NOS function (30, 38). Mechanistically,
BH4 stabilizes the functional conformation of the NOS dimer
and reduces oxidant stress both within and around the NOS
molecule (34, 38). In conditions where BH4 is limited, the
NOS dimer uncouples (4). Superoxide produced from uncou-
pled NOS further oxidizes BH4, which contributes to increased
oxidant stress and results in endothelial dysfunction (38). In
vivo human studies demonstrate that administration of exoge-
nous BH4 increases measures of NO-dependant vasodilation,
including 1) flow-mediated vasodilation in conduit arteries and
2) vasodilation in response to the endothelium-dependent ag-
onist acetylcholine in resistance vessels (9). However, the
functional role of BH4 in NOS uncoupling and its potential
contribution to attenuated NO-dependent reflex cutaneous va-
sodilation in aged humans is unclear.
The purpose of this study was to determine if exogenous
localized administration of BH4 would increase NO-dependent
reflex cutaneous vasodilation in aged humans. We hypothe-
sized that NOS uncoupling mechanisms contribute to de-
creased functional NO synthesis and attenuated reflex cutane-
ous vasodilation in aged human skin. We further hypothesized
that acute local BH4 administration or arginase inhibition,
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although mechanistically different, would similarly augment
reflex vasodilation in aged skin during passive whole body heat
stress.
METHODS
Subjects. Experimental protocols were approved by the Institu-
tional Review Board at The Pennsylvania State University. Written
and verbal consent were obtained voluntarily from all subjects before
participation according to the Declaration of Helsinki. Studies were
performed on 11 young (23  3 yr, 7 men and 4 women) and 11 older
(73  2 yr, 5 men and 6 women) healthy subjects. Subjects were
screened for neurological, cardiovascular, and dermatological dis-
eases and underwent a complete medical screening including resting
electrocardiogram, physical examination, lipid profile, blood chemis-
try (Quest Diagnostics Nichol Institute, Chantilly, VA), and V̇O2 max
test to test for the prevalence of underlying cardiovascular disease. All
subjects were normally active, nonhypertensive, nondiabetic, healthy
nonsmokers who were not taking prescription medications with pri-
mary or secondary vascular effects. Subjects who were taking 81 mg
aspirin daily as a preventative measure were required to cease treat-
ment for at least two weeks before the study visit (32). All young
women were normally menstruating and were studied during the early
follicular phase (days 1–7) of their menstrual cycle. One older subject
was retested within six weeks of their primary study visit to repeat a
control site that had failed during the initial experiment.
Instrumentation. All protocols were performed in a thermoneutral
laboratory with the subject in a semisupine position and the experi-
mental arm supported at heart level. Upon arrival to the laboratory,
subjects were instrumented with four intradermal microdialysis (MD)
fibers (10-mm, 30-kDa cutoff membrane, MD 2000; Bioanalytical
Systems, West Lafayette, IN) placed in the skin of the ventral left
forearm using sterile technique. MD sites were at least 4 cm apart to
ensure no cross-reactivity of pharmacological agents. Before MD fiber
placement, ice packs were applied to the MD sites for 5 min to
temporarily anesthetize the skin (10). For each fiber, a 25-guage
needle was inserted horizontally into the intradermal layers such that
the entry and exit points were 2.5 cm apart. MD fibers were then
threaded through the lumen of the guide needle, and the needle was
removed leaving the MD fiber in place. The MD fibers were randomly
assigned to receive 1) lactated Ringer solution to serve as control, 2)
10 mM BH4 (Sigma, St. Louis, MO) for BH4 administration, 3) 20
mM NG-nitro-L-arginine (L-NAME; Calbiochem, San Diego, CA) to
inhibit NOS, and 4) 5 mM (S)-(2-boronoethyl)-L-cysteine (BEC;
Calbiochem)  5 mM N-hydroxy-nor-L-arginine (nor-NOHA; Cal-
biochem) to inhibit arginase (18). All pharmacological agents were
mixed just before usage, dissolved in lactated Ringer solution, steril-
ized with syringe microfilters (Acrodisc; Pall, Ann Arbor, MI), and
wrapped in foil to prevent degradation of the drug due to light
exposure. During the insertion trauma resolution period (60–90 min),
solutions were perfused through the MD fibers at a rate of 2 l/min
(Bee Hive controller and Baby Bee microinfusion pumps; Bioanalyti-
cal Systems). Pilot studies were conducted to determine the optimal
concentration of BH4, defined as a dose that would augment reflex
vasodilator function but did not alter baseline SkBF. Twenty-milli-
molar L-NAME concentrations were used for NOS inhibition. We and
others have previously used 10 mM L-NAME in similar studies. In
pilot work, we find that concentrations 5 mM do not produce further
reductions in NO-dependent vasodilation, but, because of differences
that have been observed between laboratories, we opted for a higher
concentration of L-NAME. Our laboratory previously showed that a
dose of 5 mM BEC  5 mM nor-NOHA was sufficient to inhibit
arginase in young and old skin (18).
Skin temperature (Tsk) was controlled using a water-perfused suit
that covered the entire body except the head, hands, feet, and exper-
imental arm. Copper-constantan thermocouples were placed on the
surface of the skin at six different sites (calf, thigh, abdomen, chest,
shoulder, and back) to continually monitor Tsk. Each subject’s heart
rate was monitored throughout the protocol, and arterial blood pres-
sure was measured every 5 min (Cardiocap; GE Healthcare) and
verified by brachial auscultation throughout the protocol. Oral tem-
perature (Tor) was measured as an index of changes in body core
temperature using a thermistor placed in the sublingual sulcus
throughout baseline and whole body heating. Proper placement of the
sublingual thermistor was checked and verified based on temperature
readings. Once proper placement was verified, the thermistor was
taped in place, and subjects were instructed to keep their mouth closed
throughout the protocol. Tor was closely monitored throughout heat-
ing, and consistency of the probe placement was routinely ensured.
Local Tsk over each MD site was maintained at 33°C throughout
baseline and whole body heating (Moor Instruments SHO2) to ensure
any changes in SkBF were of reflex origin.
To obtain an index of SkBF, cutaneous red blood cell flux was
continually measured directly over each experimental site with an
integrated laser-Doppler flowmetry probe placed in a local heater
(MoorLab, Temperature Monitor SH02; Moor Instruments, Devon,
UK). Cutaneous vascular conductance (CVC) was calculated as red
blood cell flux divided by the mean arterial pressure (MAP) and
expressed as a percent of maximum vasodilation [%CVCmax; 28 mM
sodium nitroprusside (SNP) and local heat to 43°C]. MAP was
calculated as diastolic pressure plus one-third pulse pressure.
Experimental protocol. After MD fiber placement and the insertion
trauma resolution period, baseline data were collected (20 min).
Throughout this baseline period, mean Tsk was held at thermoneutral
by perfusing 34°C water through the suit. After baseline data were
collected, 52°C water was perfused through the suit to clamp mean
Tsk at 39°C. At a 1°C rise in Tor, mean body temperature (Tb) was
clamped by lowering the temperature of the water perfusing the suit
such that mean Tsk and Tor ceased to rise. After 5 min of steady
laser-Doppler flux values, 20 mM L-NAME was perfused through
each MD fiber at a rate of 4 ìl/min to inhibit NOS production of NO
and assess NO-dependent vasodilation within each site. L-NAME
perfusion was discontinued after laser-Doppler flux values decreased
to a steady plateau (40 min). At that time, whole body heating was
terminated, the water perfusing the suit was returned to 34°C, and
subjects were returned to thermoneutral conditions. After completion
of the whole body heating protocol, site-specific pharmacological
treatments were discontinued, and 28 mM SNP (Nitropress; Abbott
Laboratories, Chicago, IL) dissolved in lactated Ringer solution was
perfused through each MD fiber at a rate of 4 ìl/min along with
simultaneous local heating of the skin to 43°C at each site (30 min)
to obtain maximal CVC values.
Data acquisition and analysis. CVC data from the control, BH4,
NOS-inhibited, and arginase-inhibited sites were acquired at 40 Hz,
digitized, and stored on a personal computer until further data analysis
(Windaq; Dataq Instruments, Akron, OH). CVC values were averaged
over a 5-min period of stable laser-Doppler flux at baseline, for every
0.1°C rise in Tor during the whole body heating protocol, and over a
stable plateau during L-NAME perfusion. Maximal CVC values were
averaged over a stable plateau in laser-Doppler flux during perfusion
of 28 mM SNP and local heating to 43°C. Mean Tsk was calculated as
the unweighted average of the six thermocouple sites, and mean Tb
was calculated: Tb  0.9 Tor  0.1 Tsk.
NO-dependent vasodilation within each site was assessed at
clamped 1°C rise in Tor by quantifying the decrease in CVC observed
with complete NOS inhibition (20 mM L-NAME) (NO-dependent
vasodilation  CVC at 1°C rise in Tor 	 CVC plateau with L-NAME
infusion). The remaining vasodilation above baseline CVC values
following L-NAME perfusion represents NO-independent vasodila-
tion.
Unpaired Student’s t-tests were used to detect significant differ-
ences between the young and older groups for physical characteristics.
A two-way repeated-measures mixed-model ANOVA was used to
detect age and local drug differences in NO-dependent vasodilation,
and age and drug differences in maximal CVC. A two-way repeated-
measures ANOVA was used to detect significant differences in Tor,
mean Tsk, and mean Tb. A three-way repeated-measures mixed-model
ANOVA was conducted to detect age and local drug treatment
differences over the rise in Tor (version 9.1.3; SAS, Cary, NC). Post
hoc comparisons with Bonferroni corrections were performed when
necessary to determine where differences between groups and drug
treatments occurred. The level of significance was set at 
  0.05 for
main effects. Values are presented as means  SE.
RESULTS
Subject characteristics are presented in Table 1. Age groups
were well matched for body mass index, fasting blood glucose,
systolic blood pressure, diastolic blood pressure, and high-
density lipoproteins. The older subject group had significantly
higher low-density lipoproteins (LDL) and total cholesterol
than younger subjects (P  0.05).
Absolute Tor, mean Tsk, and mean Tb at baseline, a 1°C rise
in Tor (1°C Tor), 20 min into L-NAME treatment (mid-L-
NAME), and during the L-NAME plateau are presented in
Table 2. Aside from baseline, Tor and Tb were not different
between phases or age groups. Tsk was not different between
age groups but was significantly different from 1°C Tor at
baseline, 20 min into L-NAME treatment, and during L-NAME
plateau.
Figure 1 shows vasodilation (%CVCmax) as a function of
increasing core temperature (Tor) at baseline (Tor  0.0)
and during whole body heating at control, NOS-inhibited,
BH4-administered, and arginase-inhibited sites in young and
older subjects. Compared with young, older subjects exhibited
an attenuated vasodilation at the control site beginning at a
0.3°C rise in Tor. When NOS was inhibited throughout the
heating protocol (L-NAME site), young and older subjects had
similar %CVCmax responses to increased Tor. Local adminis-
tration of BH4 or local arginase inhibition significantly in-
creased the vasodilation response in older subjects compared
with their control site at a 0.1°C rise in Tor. BH4 administration
increased baseline %CVCmax in both young (control: 11 
2%CVCmax vs. BH4: 17  3%CVCmax, P  0.029) and older
(control: 11  2%CVCmax vs. BH4: 17  2%CVCmax, P 
0.029) subject groups. In the young subject group, there was no
longer a difference between BH4-treated sites and control sites
beginning at a 0.2°C rise in Tor. Arginase inhibition did not
alter baseline %CVCmax in either group.
Figure 2 shows the NO-dependent vasodilation (%CVCmax)
response at a 1°C rise in Tor at control, BH4-administered, and
arginase-inhibited sites in young and older subjects. Compared
with the control site of the older subjects, local BH4 adminis-
tration increased NO-dependent vasodilation (BH4: 32  2%
vs. control: 12  2%, P  0.0001) in the older subject group.
Arginase inhibition increased overall vasodilation in older
subjects (arginase inhibited: 47  5.0% vs. control, P  0.002)
but did not significantly increase NO-dependent vasodilation.
Neither treatment affected the total vasodilator response or
NO-dependent vasodilation in the young subject group. Com-
pared with control, NO-dependent vasodilation was signifi-
cantly attenuated at the L-NAME site in young (L-NAME:
6.4  2% vs. control: 21  4%, P  0.005) but not older
(L-NAME: 3  1% vs. control, P  0.24) subjects.
Table 3 presents maximal CVC values measured at each MD
site during combined SNP infusion and 43°C local heating.
There was a significant difference between young and old
maximal CVC values at the arginase-inhibited site (young:
2.5  0.3 vs. older: 1.5  0.3, P  0.007), but there were no
differences between younger and older subjects in the control,
BH4-, or NOS-inhibited sites.
DISCUSSION
The principal finding of this study was that local BH4
administration increased reflex cutaneous vasodilation in aged
human skin through NO-dependent mechanisms. In addition,
arginase inhibition increased vasodilation to a magnitude sim-
ilar to that of BH4 through a combination of NO and non-NO-
dependent mechanisms. These localized treatments were effec-
tive at increasing reflex cutaneous vasodilation in aged but not
young skin. These data suggest that decreased BH4 may con-
tribute to attenuated reflex vasodilation in aged human skin
possibly through limiting NO production through uncoupled
NOS. However, BH4 increased vasodilation at baseline in both
age groups, which could indicate that a portion of the increased
vasodilation in the aged may be due to a baseline shift.
Considering the putative role of BH4 in vascular function (5, 6)
and the observed restoration of total reflex cutaneous vasodi-
lation during the latter portion of the protocol with significantly
elevated body core temperatures, exogenous BH4 administra-
tion is a novel potential therapeutic target for augmenting
thermoregulatory function in aged humans.
Table 1. Subject Characteristics
Variable Young Older
Sex, M/F 7,4 5,6
Age, yr 23  1 73  2*
BMI, kg/m2 25  3 26  1
Fasting blood glucose, mg/dl 89  2 95  4
LDL, mg/dl 72  5 105  9*
HDL, mg/dl 53  5 61  4
Total cholesterol, mg/dl 142  7 182  11*
SBP, mmHg 118  4 126  3
DBP, mmHg 77  3 76  2
Values are means  SE for 11 young and 11 older subjects. M, male; F,
female; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI,
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
*P  0.05, significant difference compared with the young subject group.
Table 2. Absolute oral temperature, mean skin temperature,
and mean body temperature at baseline, 1°C rise in oral
temperature, 20 min into L-NAME and during L-NAME
plateau
Baseline 1°C Tor Mid-L-NAME L-NAME Plateau
Young
Tor 36.6  0.1* 37.6  0.1 37.6  0.1 37.7  0.1
Tsk 34.7  0.2* 39.0  0.2 37.7  0.4* 37.9  0.3*
Tb 36.4  0.1* 37.8  0.1 37.6  0.1 37.7  0.1
Older
Tor 36.7  0.1* 37.7  0.1 37.7  0.1 37.7  0.1
Tsk 35.2  0.2* 39.4  0.2 38.5  0.2* 38.4  0.2*
Tb 36.5  0.1* 37.9  0.1 37.7  0.1 37.8  0.1
Values are means  SE for 11 young and 11 older subjects. L-NAME,
NG-nitro-L-arginine methyl ester; Tor, oral temperature (°C); Tsk, mean skin
temperature averaged from 6 sites (calf, thigh, abdomen, chest, shoulder, and
back); Tb, mean body temperature (Tb  0.9 Tor  0.1 Tsk). *P  0.05,
significant difference from 1°C Tor.
In healthy young subjects, 30–40% of the full reflex
vasodilation response is mediated by NO signaling with the
other 60–70% relying on coreleased neurotransmitter(s) with
downstream vasodilation mediated through other second mes-
senger pathways and activation of cyclooxygenase (2, 28, 39).
With aging, the cofactor-mediated contribution to the overall
reflex vasodilation response is attenuated, and COX-dependent
signaling favors the production of the vasoconstrictors (12).
Consequently, older humans rely on a functionally compro-
mised NO-dependent vasodilation to increase SkBF in the heat
(11). In the present study, we have examined the involvement
of BH4 in NO-dependent mechanisms because 1) the precise
contributions and the identity of the cotransmitters in aged skin
is unknown and 2) many of these cotransmitters converge on
the NO pathway. Our results suggest that interventions focus-
ing on the NO pathways and specifically BH4 as an essential
cofactor are capable of modulating NO synthesis and increas-
ing reflex vasodilation in aged human skin.
NO is synthesized in the cutaneous vasculature by the
constitutively expressed NOS isoforms, including endothelial
NOS (eNOS) and neuronal NOS (nNOS). Kellogg et al. (23)
have reported that NO-dependent reflex vasodilation is medi-
ated exclusively by nNOS in young, healthy subjects. Although
specific eNOS inhibitors have not been used to examine the
specific contribution of this constitutively expressed isoform
on reflex cutaneous vasodilation, BH4 acts as an essential
cofactor for both eNOS and nNOS isoforms (34). Thus, NOS
is highly dependent on adequate BH4 availability for functional
NO synthesis. Furthermore, nNOS is capable of uncoupling
and producing superoxide similar to eNOS. Regardless of the
precise constitutively expressed NOS isoform mediating the
production of NO during reflex vasodilation, our data indicate
that local BH4 administration increased NO-dependent dilation
and restored the absolute magnitude of reflex cutaneous vaso-
dilation in aged human skin.
In the present study, both BH4 administration and arginase
inhibition increased vasodilation in the older subject group to
a similar magnitude, especially during the later stages of the
whole body heating protocol. These data could indicate that 1)
these treatments maximized activity through the NOS pathway
such that the enzyme was working at or near maximal velocity,
and/or 2) we had reached a ceiling effect for the ability of the
aged cutaneous vessels to vasodilate. Although both treatments
increased reflex vasodilation over control values in the aged,
neither treatment fully restored vasodilation to the values seen
in young subjects during the earlier stages of the whole body
heating protocol (Tor  0.4, 0.5, 0.6°C), possibly illustrating
the diminished contribution of cotransmitters. BH4 administra-
tion increased NO-dependent vasodilation in aged skin during
hyperthermia, resulting in restoration of total reflex cutaneous
vasodilation to a similar magnitude as observed in young at a
1°C rise in Tor. Arginase inhibition also increased total reflex
cutaneous vasodilation with a 1°C rise in Tor. However, there
was significant variability in this response, and, statistically,
we were unable to show a significant increase in NO-dependent
vasodilation (P  0.38).
BH4 administration increased baseline vasodilation in both
subject groups. During pilot work, we aimed to find a concen-
tration of BH4 that maximized NO-dependent vasodilation
while not altering baseline SkBF. However, the concentration
of BH4 used in this study modestly increased SkBF during
thermoneutral conditions. Considering that BH4 augmented
reflex vasodilation in the aged, one potential explanation for
these data could be a simple baseline shift. However, with
Fig. 1. Group mean  SE of vasodilation [cutaneous vascular conductance expressed as a percent of maximum vasodilation (%CVCmax)] response in young and
older subjects to increased core temperature (Tor) at baseline (Tor  0.0) and during whole body heating in control, nitric oxide synthase (NOS)-inhibited,
tetrahydrobiopterin (BH4)-treated, and arginase-inhibited sites. Older subjects have an attenuated vasodilation response to increased core temperature compared
with young beginning at a 0.3°C rise in Tor. BH4 administration and arginase inhibition increased the vasodilation response in older subjects compared with their
control site. BH4 administration increased baseline vasodilation in young and older subjects. *P  0.05, significant difference between BH4-administered and
control sites. †P  0.05, significant difference between L-NAME and control sites. §P  0.05, significant difference between arginase-inhibited and control sites.
increases in Tor 0.1°C, this increase in %CVCmax disappears
in the young subject group. This lack of a continuous upward
shift in vasodilation throughout body heating suggests that the
differences observed in the aged group are not simply due to a
baseline shift.
One alternate explanation for our results is that the aug-
mented reflex cutaneous vasodilation in older subjects at the
BH4-administered site is due to the antioxidant properties of
BH4 independent of its role in NOS coupling/uncoupling
status. Reducing oxidant stress through local supplementation
with ascorbate can augment the vasodilatory response in aged
skin (16). However, ascorbate has been shown to mediate its
effects on vasodilation through its protection and stabilization
of the BH4 molecule (19) and through inhibiting arginase
activation (36). Thus, direct local administration of BH4 is a
more direct way to examine NOS coupling mechanisms.
CVCmax is thought to represent the maximal structural
ability of the vessels to vasodilate and is important to assess
and present because of the normalization scheme used for
presenting the data. Differences in CVCmax are observed in
populations where vascular smooth muscle hypertrophy occurs
(i.e., essential hypertension) and therefore can greatly affect
the interpretation of the data (13, 14). In the context of vascular
aging, maximal SkBF is decreased with aging, and this de-
crease has been systematically investigated in whole limb
heating/plethysmography studies (27). In the present study, we
were not able to detect this decrease. Furthermore, we have
recently done a historical review of our aged cohort from a
series of studies over the years and have been unable to detect
differences in maximal CVC using measurements from laser-
Doppler. This is likely due to the small area of measurement
(single-point laser-Doppler) as well as the heterogeneity of the
cutaneous microvasculature. Overall, we were unable to detect
a main effect for age in maximal CVC across all sites.
Limitations. We, and others, have used Tor as an index of
body core temperature and thermoregulatory drive in studies
examining the mechanisms of active cutaneous vasodilation
(17, 22, 28, 39). Although esophageal temperature is the gold
standard technique for measurement of body core temperature,
it was not used in the current study in an effort to minimize
subject discomfort. Had we used a thermistor encased in an
esophageal probe and placed in the esophagus at the level of
the right atrium, we may have obtained more accurate core Tb
values during the heating protocol.
In this study, we performed a protocol where we clamped
mean Tb and perfused L-NAME through all sites to assess
NO-dependent vasodilation. To clamp mean Tb, we decreased
the temperature of the water perfusing the suit, uncovered the
feet, and unzipped the suit jacket by one-third for some
evaporative cooling to take place. Although mean Tb was not
significantly different between the end of heating and during
the perfusion of L-NAME, the slight changes in Tsk may have
resulted in significant changes in efferent cutaneous neural
drive. However, this alteration would have been systematic
across subjects and does not change our interpretation of the
actions of BH4 augmenting NO-dependent vasodilation in the
aged.
Older subjects had significantly greater blood total choles-
terol and LDL concentrations than young subjects. We have
recently demonstrated that increased LDL and specifically
oxidized LDL increases arginase activity and limits cutaneous
NO-dependent vasodilation (15). These latest data suggest the
possibility that the observed effects in the present study may be
due to elevated cholesterol and/or LDL. However, the older
subject group had LDL and total cholesterol concentrations
below 120 and 200 mg/dl, respectively. These values classify
the older subject group as nonhypercholesterolemic according
to the guidelines set by the American Heart Association.
Furthermore, these values are not significantly different from
the normocholesterolemic control group used in our previous
experiments. However, it remains possible that some of the
changes observed with the aged group in respect to attenuated
Fig. 2. Group mean  SE of nitric oxide (NO)-dependent vasodilation
(%CVCmax) response in young and older subjects at a 1°C rise in Tor in control,
BH4-administered, arginase-inhibited, and NOS-inhibited [NG-nitro-L-arginine
methyl ester (L-NAME)] sites. The complete bars represent the mean response
at a 1°C rise in Tor. The black bars represent the mean plateau response after
NOS inhibition (L-NAME, 20 mM) within the site at a clamped 1°C rise in Tor.
The mean decrease from the peak response to L-NAME plateau represents
NO-dependent vasodilation at a 1°C rise in Tor (NO-dependent vasodilation 
CVC at 1°C rise in Tor 	 CVC plateau with L-NAME infusion). BH4
administration increased overall vasodilation and NO-dependent vasodilation
in older subjects. Arginase inhibition increased overall vasodilation in older
subjects. L-NAME significantly decreased NO-dependent vasodilation in
young but not older subjects compared with control. *P  0.05, significant
difference in vasodilation compared with older control. ‡P  0.05, significant
difference in NO-dependent vasodilation compared with older control. †P 
0.05, significant difference from young control.
Table 3. Absolute maximal CVC (sodium nitroprusside
perfusion, 28 mM  local heat, 43°C) measured at each
intradermal microdialysis site
Site Maximal CVC
Control young 1.9  0.2
Control older 1.4  0.2
NOS-inhibited young 2.3  0.3
NOS-inhibited older 1.6  0.2
BH4 young 1.7  0.2
BH4 older 2.0  0.3
Arginase-inhibited young 2.5  0.3
Arginase-inhibited older 1.5  0.3*
Values are means  SE. CVC, cutaneous vascular conductance; NOS, nitric
oxide synthase; Control, lactated ringer; NOS-inhibited, L-NAME; BH4,
tetrahydrobiopterin administration. All sites received L-NAME before quan-
tification of maximal CVC. *P  0.05 compared with young within site.
NO-dependent vasodilation may be in part due to increased
total and LDL cholesterol.
Perspectives. Our results suggest that local BH4 administra-
tion increases reflex vasodilation in aged skin. In addition,
local BH4 administration augments reflex cutaneous vasocon-
striction induced by whole body cooling in older subjects
through its proposed role as an essential cofactor for tyrosine
hydroxylase and subsequent norepinephrine synthesis (25).
Cumulatively, this series of studies suggests that BH4 may play
a dual role in the control of SkBF through its actions as an
essential cofactor for monoamine oxidase. Therefore, systemic
administration of exogenous BH4 may have positive effects on
thermoregulatory function in aged humans provided target
tissue concentrations can be increased sufficiently. Oral sup-
plementation with pharmacological preparations of BH4 is a
commonly utilized therapy for patients with BH4-responsive
phenylketonuria (8). Additionally, oral supplementation with
BH4 improves vascular function in animal and human models
of vascular dysfunction (3, 33). These data suggest that oral
supplementation strategies may be an effective intervention for
improved microvascular function in the aged and may expand
the range of blood flow responses to both heat and cold in the
aged cutaneous vasculature.
In summary, local BH4 administration increases reflex cu-
taneous vasodilation in aged human skin through NO-depen-
dent mechanisms. In addition, arginase inhibition increases
vasodilation to a similar magnitude. These localized treatments
were effective at increasing reflex cutaneous vasodilation in
aged but not young skin. These data suggest that decreased
BH4 may contribute to attenuated reflex vasodilation in aged
human skin possibly through limiting NO production through
uncoupled NOS. Considering the putative role of BH4 in
vascular function and the observed restoration of total reflex
cutaneous vasodilation from the current study, exogenous BH4
administration is a potential therapeutic target for augmenting
thermoregulatory function in aged humans.
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